Meloxivet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxivet

Quick Facts

Property Description
Active Ingredient Meloxicam
Forms Injectable solution, Oral suspension, Tablets
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Pain relief, inflammation, and fever reduction
Origin Synthetic organic compound

The Definitive Classification: What Type of Medicine is Meloxivet?

Meloxivet is a pharmaceutical product containing the active substance Meloxicam, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification means the medicine is intended to counteract inflammation and reduce pain across the body. Chemically, Meloxicam is an oxicam derivative, belonging to the enolic acid class of NSAIDs. Meloxicam is uniquely characterized by its preferential selectivity for the cyclooxygenase-2 (COX-2) enzyme, which distinguishes its profile from older, less selective NSAID compounds.

Composition, Origin, and Available Forms

The active substance, Meloxicam, is a synthetic organic compound produced through chemical synthesis, establishing its origin as non-naturally occurring. The medicine is consistently provided as a single-ingredient formulation. Meloxivet is commonly available in several distinct dosage forms, notably including an injectable solution for parenteral administration and an oral suspension or tablet for ingestion. This dual availability—oral and parenteral—is a key differentiating feature that provides greater flexibility in patient management compared to medications restricted to a single route of administration.

Core Purpose and Therapeutic Role

The general purpose of Meloxivet is to provide systemic relief by addressing the primary physical signs of disease that involve discomfort. The therapeutic action stems from the ability of Meloxicam to interrupt the production of prostaglandins, the chemical mediators that drive pain, inflammation, and fever. Consequently, the product is clinically recognized for its three core effects: it is analgesic for pain relief, anti-inflammatory to reduce swelling, and antipyretic for lowering elevated body temperature. In essence, the product's primary role is centered on modulating these fundamental biological responses to improve patient comfort.

Regulatory References

  1. NIH: MedlinePlus Drug Information

What side effects are possible with Meloxivet?

Possible side effects and safety information

The official regulatory safety profile for Meloxivet, containing Meloxicam, outlines adverse reactions grouped by frequency and affected organ system, based on clinical data documented by government authorities.

Adverse Reaction Scope

Classification Tier Primary System-Organ Classes Involved
Very Common Gastrointestinal disorders (e.g., dyspepsia, nausea, diarrhea)
Common Nervous system disorders (e.g., headache, dizziness), General disorders (e.g., edema)
Uncommon Blood and lymphatic system disorders (e.g., anemia), Skin and subcutaneous tissue disorders (e.g., rash)

Serious Adverse Reactions

Regulatory documents emphasize the potential for serious cardiovascular thrombotic events, including myocardial infarction and stroke, which may occur early in treatment. The label also documents the risk of serious gastrointestinal events, such as bleeding, ulceration, and perforation, which can be fatal and may occur without warning symptoms. Additionally, rare, but severe, bullous skin reactions (like Stevens-Johnson syndrome) and acute renal failure are documented.

Safety Considerations and Restrictions

  • Population-Specific Safety: Older adults are formally noted as being at higher risk for serious gastrointestinal complications. Use is generally restricted in individuals with severe hepatic or severe, non-dialyzed renal impairment.
  • Duration-Related Patterns: The risk of serious cardiovascular and gastrointestinal events is noted to increase with the duration of use.
  • Contraindications: The medicine is restricted in patients with a history of NSAID-induced asthma or hypersensitivity and is formally contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Resulting Safety Structure

Regulatory safety summary:

  • The safety profile is structured to communicate the high incidence of common gastrointestinal discomfort against the critical, though less frequent, serious cardiovascular and gastrointestinal risks.
  • Official documentation highlights that the most significant safety concerns are associated with the gastrointestinal and cardiovascular systems.
  • Regulatory guidelines define specific groups, such as the elderly and those with severe organ impairment, as requiring particular safety consideration.

Connection to the overall safety profile: The formal safety profile defines the medicine's risk landscape by clearly separating the most commonly expected side effects from the serious adverse reactions that government bodies require be highlighted. This regulatory structure emphasizes that the risk of the most serious events is linked to both the duration of use and pre-existing patient conditions, thereby establishing the official boundaries for safety.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate Medical Attention is Required

If you take more than the prescribed dose, contact a doctor, hospital emergency department, or a regional Poison Control Center immediately. Overdosing on an NSAID like Meloxivet can lead to serious and potentially life-threatening complications.

Recognizing Overdose Symptoms

Symptoms following an acute overdose are often consistent with nonsteroidal anti-inflammatory drug (NSAID) toxicity, though experience with Meloxivet's active ingredient, meloxicam, is limited. Initial, generally reversible symptoms may include lethargy, drowsiness, nausea, vomiting, and epigastric pain (pain in the upper central abdomen).

However, severe poisoning may result in more dangerous clinical manifestations, including:

  • Gastrointestinal bleeding
  • Acute renal failure or hepatic dysfunction
  • Cardiovascular complications (hypertension, collapse, or cardiac arrest)
  • Neurological symptoms (convulsions, coma, respiratory depression)
  • Anaphylactoid reactions (severe allergic-like response)

Overdose Risk Factors

Taking more than the recommended dose increases the risk of serious and dangerous effects, particularly for the elderly or those with pre-existing conditions like renal disease or who are taking other medications.

Emergency Actions

Management in an overdose situation is supportive and symptomatic. Medical professionals may recommend administration of activated charcoal if the ingestion was recent (within 1–2 hours) or, in severe cases, may use Cholestyramine to accelerate the elimination of the medication from the body. Forced diuresis or dialysis is typically not beneficial due to the drug's high protein binding.

Therapeutic Uses of Meloxivet

The medicine is commonly used to provide symptomatic relief for conditions involving inflammatory and irritative processes.


Supportive Relief for Symptoms that Interfere with Functioning

Meloxivet is primarily applied to address symptoms related to physical discomfort in chronic conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It generally contributes to improved day-to-day comfort by helping ease the persistent pain, stiffness, and swelling that interfere with daily functioning.

It is also used in clinical settings that require short-term symptomatic assistance, managing acute pain flares or the inflammation following surgical or dental procedures. This application supports the patient by addressing the pronounced symptoms of pain, swelling, and elevated body temperature (fever), helping to ease the overall symptom burden when manifestations become more disruptive.


Quick Fact: Relief for Joint and Systemic Discomfort

Symptom Domain Key Therapeutic Benefit Clinical Context
Chronic Joint Pain & Stiffness Helps ease daily symptom burden Long-term management of Rheumatic disease
Acute Inflammation & Discomfort Supports functional stability Post-operative or acute pain episodes
Systemic Symptoms Applied to ease pain, swelling, and fever Situations involving inflammatory responses

Eligibility and Restrictions for Use

Who Can and Cannot Use Meloxivet?

The population eligibility for Meloxivet (Meloxicam) is strictly defined by regulatory authorities and is based on a formal assessment of who can safely use the medication. Eligibility is constrained by age, pre-existing health status, and hypersensitivity history.


Populations Officially Approved for Use

Age Group Approved Indication Status
Adults Approved for use in Osteoarthritis and Rheumatoid Arthritis.
Pediatric Patients Approved for use in Juvenile Rheumatoid Arthritis in patients 2 years of age and older.

Absolute Contraindications (Must Not Use)

Meloxivet is formally contraindicated in the following circumstances and populations:

  • Patients with known hypersensitivity or severe allergic reactions (e.g., asthma, urticaria) to aspirin or other NSAIDs.
  • Individuals undergoing the setting of coronary artery bypass graft (CABG) surgery.
  • Women who are in the third trimester of pregnancy (at or after 30 weeks gestation).
  • Patients with active or recurrent peptic ulcer/haemorrhage or a history of gastrointestinal bleeding related to prior NSAID therapy.
  • Individuals with severe renal impairment not on dialysis or severely impaired liver function.

Note on Restricted Use: The medicine is generally not recommended for use in children under two years of age, as safety and efficacy have not been established in this younger population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Meloxivet (Meloxicam), as an NSAID, has documented interaction patterns that are classified by regulatory agencies based on the potential to alter drug exposure or increase the risk of specific adverse outcomes.

Documented Drug–Drug Interaction Risks

Co-administration with other NSAIDs or salicylates (including non-analgesic doses of aspirin) is generally not recommended due to an officially recognized, increased risk of serious gastrointestinal events, such as bleeding and ulceration. The oral suspension formulation is contraindicated with Sodium Polystyrene Sulfonate (Kayexalate).

Meloxivet increases the risk of bleeding complications when co-administered with anticoagulants, antiplatelet agents, and Selective Serotonin Reuptake Inhibitors (SSRIs).

Exposure and Therapeutic Interference

The medicine is documented to interfere with the efficacy of certain cardiovascular and renal drugs. Co-administration with ACE inhibitors, ARBs, or diuretics may diminish their antihypertensive or natriuretic effects and increase the risk of acute renal impairment, particularly in vulnerable patients.

Pharmacokinetic interactions are documented with Lithium and Methotrexate, where Meloxivet increases the plasma concentrations of these drugs. Conversely, Cholestyramine is noted in official documents to accelerate the clearance of Meloxicam from the plasma.

Interactions with Other Substances

Official information notes that consuming alcohol while taking Meloxivet may increase the risk of stomach bleeding. Specific herbal products, such as Ginkgo biloba, may also increase bleeding risk due to antiplatelet properties.

Mechanism of Action

How Meloxivet Works: The Mechanism of Action

Preferential Targeting of Pro-Inflammatory Enzymes ( COX-2)

Meloxivet's core mechanism is the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme, which is upregulated at sites of tissue damage. This action blocks the initial molecular step of the Arachidonic Acid Pathway that generates chemical messengers responsible for initiating physiological responses. This action modulates signaling resulting from heightened inflammatory pathway activation.


Modulating Systemic Prostaglandin Signaling

The consequence of COX-2 inhibition is a reduced synthesis of prostaglandins, lipid mediators that regulate nerve sensitivity and body temperature. This modification of humoral signaling alters the activity of peripheral pain nerves (anti-nociception) and adjusts the central temperature set-point (antipyresis).


Limiting Mechanistic Action: The Role of Preferential Selectivity

The mechanism is defined as preferential rather than strictly specific. This characteristic indicates that the mechanism includes some degree of COX-1 influence, preventing its action from being perfectly confined to the pro-inflammatory signaling cascade. The COX-1 enzyme maintains a constitutive role in several physiological processes.

Dosage and Administration Information

Instruction Map: How to use Meloxivet — administration guidelines

Instruction Map: How to use Meloxivet — administration guidelines
Administration scope
Route of administration: Oral (tablets, suspension) and Intravenous (IV) injection.
Dosing schedule: Starting Oral Dose: 7.5 mg once daily. Max Oral Dose: 15 mg once daily. Max IV Dose: 30 mg once daily.
Timing in relation to meals (if applicable): May be taken without regard to the timing of meals; some guidelines advise taking with food.
Preparation requirements (if applicable): Oral Suspension must be shaken gently before use. IV injection is administered as a bolus over 15 seconds.
Age-group administration rules: Hemodialysis Patients: Max oral dose is limited to 7.5 mg. Elderly/High-Risk: Start with 7.5 mg for long-term use.
Missed-dose rules: Take the missed dose as soon as remembered; if near the next dose, skip the missed one. Do not take a double dose.
Special procedural conditions: Use the lowest effective dose for the shortest duration. Oral forms are not considered interchangeable.
--- ---
Instruction classifications (high-level)
Administration method type (oral / IV / topical / inhaled / etc.): Oral and Intravenous.
Frequency pattern (daily / weekly / as-needed, etc.): Once daily (qDay).
Guideline basis: Standardized protocols.
Use-context constraints: Must adhere to population-specific dose maximums and the principle of shortest duration of use.
--- ---
Resulting procedural structure
Step sequence:
Administer the dose as a single, once-daily amount via the appropriate route (oral or IV).
Adhere to the established 7.5 mg starting dose, or the maximum 15 mg oral limit.
For oral tablets, note the score line is for swallowing facilitation only, not for division.
Maintain adherence to special rules for duration and population (e.g., hemodialysis maximum).
--- ---
Connection to the overall use protocol (2–4 sentences): The administration protocol is defined by the requirement to administer a single dose once daily across all approved routes. This framework dictates precise milligram limits—such as the 15 mg maximum oral dose and the stricter 7.5 mg limit for certain patient groups—to standardize the use pattern. The procedural structure, including the specific IV bolus timing, ensures that the medicine is delivered according to established guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Meloxivet

Research examined pain outcomes reported by participants and whether differences in objective inflammatory markers were observed. A large-scale meta-analysis reviewed data from 15 separate randomized trials.

  • Primary Findings: The study results indicated a statistical difference in the primary outcome of participant-reported pain between groups.
  • Persistence of Outcomes: Follow-up studies investigated how long outcomes, if any, persisted.
  • Study Parameters: Research protocols used a pre-determined dosage for measurement of all primary endpoints.

Investigating Combination Therapy

Studies assessed a combination regimen, examining the time to reported change in symptoms compared to Meloxivet alone. Research evaluated changes in joint mobility measures reported by participants.

  • Study Design: The primary research was conducted via a 6-month, double-blind, randomized controlled trial (RCT).
  • Mechanism of Action: A major trial investigated Meloxivet’s proposed mechanism of action, focusing on a specific molecular pathway. This finding requires further research.

Outcomes and Tolerability Data

Studies also explored long-term participant outcomes, including changes in functional status. Findings regarding these endpoints were mixed, with some studies documenting a change and others documenting none.

  • Tolerability Profile: The research documented all observed events and participant-reported outcomes related to tolerability. The documented events did not meet the criteria for study discontinuation in most cases.
  • Specific Populations: Research on participants with pre-existing conditions, such as mild to moderate liver impairment, was conducted, with researchers noting outcomes specifically among participants who had pre-existing liver conditions. Research has not yet established outcomes for participants with severe liver or kidney conditions.

Frequently Asked Questions (FAQ)

Common questions about Meloxivet (FAQ)

Q: How long does it typically take for Meloxivet to start working?

Meloxivet is primarily used for chronic pain conditions, and its full anti-inflammatory effect may require a few days of consistent use to be observed. Due to the nature of this type of medication, a full anti-inflammatory effect may be gradual, and official documents note that the injectable form is not recommended when rapid pain relief is needed.

Q: What is the expected duration of pain relief from a single dose of Meloxivet?

The official product information supports a once-daily administration schedule. This is due to the drug's half-life, which allows the medication to maintain therapeutic concentrations for a prolonged period in the body.

Q: Can Meloxivet affect heart health or blood pressure?

Regulatory warnings indicate that Meloxivet, like other NSAIDs, may cause the new onset or worsening of pre-existing high blood pressure (hypertension). This is one of the factors that can increase the risk of serious cardiovascular events. Monitoring of blood pressure is important during treatment.

Q: Can Meloxivet cause fluid retention or swelling in the hands and feet?

Yes, official safety information lists edema, which is fluid retention and swelling, as a common adverse reaction associated with the use of NSAIDs. Patients with a history of heart failure should be monitored for fluid retention during treatment.

Q: Can Meloxivet be taken at the same time as Tylenol (acetaminophen)?

There is no explicit contraindication listing a specific drug-drug interaction between Meloxivet and acetaminophen (Tylenol) in official product information. Consulting official product information or a healthcare professional is recommended for clarification on co-administration.

Q: What is the potential interaction between Meloxivet and antidepressant medications?

Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs), a common type of antidepressant, is noted in official regulatory documents. This combination is associated with an increased risk of bleeding complications.

Q: Is it safe to drink alcohol in moderation while taking Meloxivet?

Official warnings state that consuming alcohol while taking Meloxivet may increase the risk of serious gastrointestinal events, specifically stomach bleeding. The official warning indicates that caution regarding alcohol consumption is necessary during treatment.

Q: Is Meloxivet safe to take during pregnancy, particularly in the later stages?

Meloxivet is formally contraindicated (must not be used) in the third trimester of pregnancy (at or after 30 weeks gestation). Use between 20 and 30 weeks should be limited to the lowest effective dose for the shortest duration possible.

Q: What happens if I miss a dose of Meloxivet?

Official administration rules state that if you miss a dose, you should take it as soon as you remember. However, if it is close to the time for your next scheduled dose, the missed dose should be skipped entirely. A double dose must never be taken to compensate for a missed one.

Q: Does taking Meloxivet with food help reduce stomach upset?

The official prescribing information indicates that Meloxivet may be taken without regard to the timing of meals. However, taking it with food is a general practice for NSAIDs and may help minimize the risk of stomach upset, as advised by some official European labels.

Q: Is the Meloxivet oral suspension interchangeable with the tablets?

Official administration rules explicitly state that the oral suspension and tablets are not considered interchangeable. This is because they are not therapeutically equivalent in terms of absorption.

Q: What should I do if my stomach feels upset after taking Meloxivet?

Upset stomach (dyspepsia) is listed as a very common side effect. If stomach upset occurs, taking the medication with food is a general practice for NSAIDs that may help. Severe symptoms, such as signs of bleeding, like black or bloody stools, require immediate medical attention.

Q: Is Meloxivet considered a fast-acting pain reliever?

While Meloxivet does have pain-relieving properties, official documentation related to the injectable form notes that it is not recommended when rapid onset of analgesia (pain relief) is required. The full anti-inflammatory benefits may be established more gradually.

Q: Why is Meloxivet often a once-daily medication compared to other pain relievers?

Meloxivet is typically a once-daily drug due to its prolonged half-life. This characteristic allows it to maintain therapeutic concentrations in the body, supporting the once-daily dosing regimen.

Q: What are the most common or minor side effects people experience with Meloxivet?

Based on clinical trial data, the most common adverse events include gastrointestinal issues like diarrhea and indigestion (dyspepsia), and central nervous system effects such as headache. These generally occur more frequently than serious side effects.

Q: Is it normal to feel dizzy or have a headache when starting Meloxivet?

Yes, regulatory information lists both headache and dizziness as common adverse reactions reported in clinical trials. These are considered typically mild to moderate side effects.

Q: Does Meloxivet cause drowsiness or affect alertness?

Official safety data lists drowsiness (somnolence) as an adverse reaction that has been reported by patients in clinical studies. Patients should be aware of this potential effect.

Q: What are the risks associated with long-term use of Meloxivet?

The risk of serious side effects, particularly cardiovascular thrombotic events and severe gastrointestinal events, is noted to increase with the duration of use. Official guidance advises using the lowest effective dose for the shortest duration possible.

Q: Can Meloxivet affect kidney function?

Yes, the medication carries a warning for renal toxicity (kidney damage). Official prescribing information notes that caution and monitoring are necessary for vulnerable patients, and it is contraindicated in patients with severe, non-dialyzed renal impairment.

Q: Can people with high blood pressure safely take Meloxivet?

Official warnings advise caution when using this medication in patients with pre-existing high blood pressure. Meloxivet can potentially worsen hypertension, and it may also interfere with certain blood pressure-lowering medications.

Q: Is Meloxivet an appropriate medication for older adults (65 and over)?

Older adults (aged 65 years and over) are officially noted as being at higher risk for serious gastrointestinal complications. Therefore, a lower starting or maximum dose is often used in this population.

Q: Can Meloxivet be used by children, and for what conditions?

Yes, Meloxivet is approved for use in the pediatric population for the treatment of Juvenile Rheumatoid Arthritis (JRA). This use is specifically approved for children 2 years of age and older.

Q: Can Meloxivet impact fertility or a woman's ability to conceive?

Official product information notes that the use of NSAIDs may impair female fertility and is generally discouraged for women who are actively trying to conceive.

Q: Is Meloxivet addictive or habit-forming?

Meloxivet is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official regulatory documents do not indicate that it is a controlled substance, addictive, or habit-forming.

Q: Why do some Meloxivet formulations require caution for people with phenylketonuria (PKU)?

Some oral dosage forms, such as orally disintegrating tablets, may contain phenylalanine as an inactive ingredient. Official labeling includes a specific warning regarding this component for patients with phenylketonuria (PKU).

Q: Is Meloxivet only for chronic pain, or can it be used for short-term pain relief?

Meloxivet is officially indicated for long-term chronic conditions like Osteoarthritis and Rheumatoid Arthritis. However, it is also approved for the short-term management of moderate-to-severe pain.

Q: Can Meloxivet cause sensitivity to sunlight or skin rashes?

Official safety information notes that skin rash is an uncommon adverse reaction. Patients are advised to stop the medication and seek care at the first appearance of a skin rash or other signs of hypersensitivity, which can include photosensitivity (increased sensitivity to light).

Q: Can Meloxivet interfere with other conditions like asthma or allergies?

Yes, it is formally contraindicated in patients with a history of asthma or other allergic-type reactions (like hives) caused by aspirin or other NSAIDs. Caution is also advised when administering to patients with pre-existing asthma.

Q: Can Meloxivet cause changes in mood or behavior?

Adverse reactions affecting the central nervous system have been reported. These include changes in mood, behavior, and sleep patterns, such as anxiety, mild depression, and abnormal dreaming.

Q: Is there a chance Meloxivet can cause ringing in the ears (tinnitus)?

Yes, tinnitus, which is a ringing or buzzing in the ears, has been documented as a possible side effect of Meloxivet in official adverse reaction reports or post-marketing experience.

Q: What are common user experiences with weight gain/loss while taking Meloxivet?

While significant weight change is not listed as a primary side effect, the medication can cause fluid retention and edema (swelling). This fluid retention may present as an unexplained or sudden weight gain.

How should Meloxivet be stored and disposed of?

Storage and Disposal Map: Meloxivet Official Regulatory Information

The correct handling and storage of Meloxivet (meloxicam) must adhere strictly to regulatory standards to maintain stability and ensure safety.

Requirement Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature (CRT), typically 68 F to 77 F (20 C to 25 C).
Protection and Handling Protect from moisture and light; keep from freezing. Store in the original container and keep the container tightly closed.
Stability After Opening The oral suspension generally has a defined shelf-life after first opening of 6 months.
Disposal All unused or expired product must be disposed of in accordance with local regulations; do not keep outdated medicine.
Child Safety Keep out of the reach and sight of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloxivet found in:

A-Z Index: